SPOTLIGHT -
Key Long COVID Symptoms Persist for Nearly 2 Years, But Many Return to Work
A new report tracking patients suggests that even those who return to work experience persistent symptoms.
Read More
Study Identifies Links Between Gut Dysbiosis and COVID-19
The data may help explain why COVID-19 patients experience dangerous secondary infections.
Significant Barriers Keep Patients from Adopting Injectable PrEP
The study showed, however, that physicians can help solve the problem if they are willing to answer patient’s questions about the therapy’s efficacy and safety.
Vitamin D Supplementation Appears to Offer Protective Benefits Against COVID-19
A new report finds veterans who took vitamin D supplements were less likely to get COVID-19 and less likely to die within 30 days of infection.
Measuring Disease Severity, Quality of Life in Japanese Hepatitis Patients
As viral hepatitis is the most common blood-transmitted infection globally, assessing the toll of hepatitis and hepatitis-related conditions is critical.
GSK Halts Trials of new UTI Treatment Gepotidacin for Efficacy
The company says it plans to begin talking with regulators next year after seeing positive efficacy data in the trials.
CDI Biotherapeutic RBX2660 Outperforms Placebo in Phase 3 Trial
The closely watched therapeutic candidate led to long-term responses in 90% of patients who benefited from the therapy.
By Raising Awareness of C diff, Foundation Hopes to Minimize Risk
November is Clostridioides difficile (C diff) awareness month. The Peggy Lillis Foundation hopes to use the month to increase the public’s awareness of the dangers of the infection.
Hepatitis A Vaccination Program Works, But Migration Complicates Impact
Over the past decade, the number of cases of hepatitis A infection at a Turkish hospital has decreased, but a growing proportion of cases come from migrants to the country.
Among People with Hemophilia, HCV Prevention is Working, But Eradication Remains Elusive
A new review article suggests it is possible to eradicate hepatitis C virus infections among people with hemophilia, but it will take intense focus from public health agencies.
Bivalent SARS-CoV-2 Vaccine Might Offer Better Omicron Protection
Interim data show a bivalent vaccine that contains the Omicron variant may be more effective.
HIV Prevalence High Among Female Sex Workers But Interventions Have Positive Effect
There are a number of programs designed to help lower rates of infection and transmission amongst this industry's workforce in South Africa.
Causation Prediction Tool May Lower Rates of Pediatric Antibiotic Prescriptions for Diarrhea
When physicians were told that a case was likely viral they were less likely to prescribe antibiotics, a new study shows.
Most People with HCV Infection Are Not Treated with Direct-Acting Antivirals
A new report underscores a persistent problem of patients not receiving antivirals despite their high curative rate.
Report Finds "Mix-and-Match" COVID-19 Booster Approach More Effective
People who initially received an mRNA vaccine but were boosted with the Janssen vaccine had superior immune responses, the study found.
HIV Associated with Rapid Age Acceleration, New Study Finds
The study was longitudinal in nature, comparing at-risk people who became infected with HIV to at-risk people who did not.
Regular COVID-19 Screening in Schools Can Control Infections, Limit Closures
The model suggests screening unvaccinated students could reduce absences by 80% compared to reactively closing classes with infected students.
Report: COVID-19 Had Dramatic Effect on Life Expectancies of Poor and Minorities
Though all racial and ethnic groups saw declines in life expectancy, the impact was greater among members of minority groups.
Flu Vaccine Protects Against Death, Recurrent Hospitalizations in Older Patients with CVD
The report showed the protective benefits varied somewhat by cardiovascular disease subtype.
Omicron SARS-CoV-2 Surge Led to Surge in Hospital Infections, Too
A new analysis from a Massachusetts health system found in-hospital infections occurred at a higher rate when the Omicron variant was present compared to when wild-type SARS-CoV-2 was prevalent.
Against COVID-19, Both Natural and Vaccination-Mediated Protection Wane Over Time
Patients with a history of infection who were also vaccinated had the strongest protection, the data showed.
As Omicron Spreads, Public Health Officials Ponder When to Update COVID-19 Vaccine
Rather than developing vaccines for each new variant, some officials are pushing to follow the flu vaccine model, with annual vaccination.
RBX2660 Prolongs Time to Recurrence in Patients with CDI Infection
Patients who took RBX2660 following antibiotic therapy had lower rates of recurrence and double the time to recurrence, compared to patients taking placebo.
RBX2660 Cuts Risk of Recurrence in Patients with Multiple C Diff Infections
The microbiota-based live therapeutic had a 68.3% success rate when administered following antibiotic treatment, versus a 55% success rate in a placebo group.
In C Diff, New Attention Being Paid to the Role of the Virome
Most of the discussion around fecal microbiota transplantation has focused on bacterial communities, but new advances have shed more light on the role of the virome.
Rifaximin Effective in Majority of Patients Recurrent CDI Who Do Not Respond to Metronidazole
About 65% of patients with metronidazole-resistant recurrent C difficile infection benefitted from taking rifaximin.
Engineered Live Biotherapeutic Could Eliminate Gut Impacts of Antibiotics
In a mouse model, the product protected against C difficile without eliminating the antibiotic’s presence in the blood.
Metabolic Network Analysis Helps Clarify Drivers of Virulence in C Difficile
The technology platform could speed up the development of novel therapeutics to combat virulence.
Continuous Enteral Vancomycin Helpful in Cases of Severe Recurrent CDI
In a small retrospective study, 7 of 11 patients experienced clinical improvement.
Recurrent CDI Therapy RBX2660 Shows Durable Efficacy in Phase 2 Results
Nearly 8 in 10 patients with recurrent C. diff. Infection were successfully treated after up to 2 doses of the microbiota-based therapy.